This week we've had EyesOn all the recent Business Development activities in the BioPharma world. We're sharing a few that caught our eye. Check out AbbVie's acquisition of Apogee to strengthen out their I&I portfolio, Sangamo's asset sale, and Pfizer's recent clinical results from one of their Seagen candidates.

Business Development as a Strategic Lever: Looking at how Biopharma Companies are tapping into a mix of Acquisitions, Licensing, and Partnerships to Reposition for Growth

Pharma Phriday (June 12, 2026). Oral drug delivery continued to reshape the obesity and HIV treatment landscapes. AI platform deals deepened beyond pilots into multi-year operational commitments. BD&L activity was substantial, spanning late-stage acquisitions, platform licensing, and preclinical bets. Regulatory milestones touched rare disease, oncology, and haematology. Several long-standing therapeutic hypotheses were either validated or refuted by Phase III data.

A landmark week across oncology, with pivotal data in lung, prostate, bladder, and haematological cancers reshaping treatment paradigms in both early and advanced disease. Gene editing, RNA therapeutics, and AI drug discovery attracted major capital commitments. Kidney disease emerged as a strategic battleground. A persistent US drug pricing gap versus other high-income countries remained unresolved.